David Ross Camidge

2.5k total citations
16 papers, 337 citations indexed

About

David Ross Camidge is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Ross Camidge has authored 16 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in David Ross Camidge's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Medical Imaging Techniques and Applications (2 papers). David Ross Camidge is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Medical Imaging Techniques and Applications (2 papers). David Ross Camidge collaborates with scholars based in United States, Japan and France. David Ross Camidge's co-authors include Frank G. Haluska, Lyudmila Bazhenova, Ravi Salgia, Alice T. Shaw, Rafael Rosell, Timothy Piers Clackson, David Kerstein, Scott Gettinger, Corey J. Langer and David J. Dorer and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Oncotarget.

In The Last Decade

David Ross Camidge

15 papers receiving 335 citations

Peers

David Ross Camidge
Kaoru Irisa Japan
Timothy Piers Clackson United States
Sabine Glaser Switzerland
Luigi Cerbone Italy
James D. Peyton United States
Carmen G. Rea Italy
Gregory J. Gerstner United States
Kaiqi Du China
Domnita-Ileana Burcoveanu France
S.T. Kim South Korea
Kaoru Irisa Japan
David Ross Camidge
Citations per year, relative to David Ross Camidge David Ross Camidge (= 1×) peers Kaoru Irisa

Countries citing papers authored by David Ross Camidge

Since Specialization
Citations

This map shows the geographic impact of David Ross Camidge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ross Camidge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ross Camidge more than expected).

Fields of papers citing papers by David Ross Camidge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ross Camidge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ross Camidge. The network helps show where David Ross Camidge may publish in the future.

Co-authorship network of co-authors of David Ross Camidge

This figure shows the co-authorship network connecting the top 25 collaborators of David Ross Camidge. A scholar is included among the top collaborators of David Ross Camidge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ross Camidge. David Ross Camidge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Goldman, Jonathan W., Shun Lü, Jair Bar, et al.. (2025). LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR -wildtype advanced NSCLC: Efficacy outcomes by prior therapy.. Journal of Clinical Oncology. 43(16_suppl). 8618–8618. 1 indexed citations
3.
4.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8597–8597. 1 indexed citations
5.
Barlési, Fabrice, Enriqueta Felip, Sanjay Popat, et al.. (2024). Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).. Journal of Clinical Oncology. 42(16_suppl). TPS8653–TPS8653. 4 indexed citations
6.
Aggarwal, Charu, Alex Martínez‐Martí, Margarita Majem, et al.. (2024). Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8046–8046. 8 indexed citations
7.
8.
Camidge, David Ross, Jair Bar, Hidehito Horinouchi, et al.. (2024). Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.. Journal of Clinical Oncology. 42(16_suppl). 103–103. 8 indexed citations
9.
Gupta, Neeraj, Karen L. Reckamp, David Ross Camidge, et al.. (2022). Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC. Clinical and Translational Science. 15(5). 1143–1154. 5 indexed citations
10.
Patil, Tejas, et al.. (2022). Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Frontiers in Oncology. 11. 788245–788245. 2 indexed citations
11.
Ng, Terry L., David Chun Cheong Tsui, Sherry Wang, et al.. (2022). Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001. Cancer Medicine. 11(23). 4422–4429. 6 indexed citations
12.
Byers, Lauren A., Leora Horn, Goetz Kloecker, et al.. (2017). A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget. 8(46). 81441–81454. 14 indexed citations
13.
Gettinger, Scott, Lyudmila Bazhenova, Corey J. Langer, et al.. (2016). Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet Oncology. 17(12). 1683–1696. 261 indexed citations
14.
Wakelee, Heather A., Jonathan W. Goldman, Shirish M. Gadgeel, et al.. (2016). PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S311–S312. 1 indexed citations
15.
Damm‐Welk, Christine, Matthias Fischer, Barbara Hero, et al.. (2016). Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. Journal of Cancer. 7(11). 1383–1387. 9 indexed citations
16.
Venook, Alan P., Maria E. Arcila, Al B. Benson, et al.. (2014). NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. Journal of the National Comprehensive Cancer Network. 12(11). 1629–1649. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaoru Irisa Breakdown of academic impact, for papers by Timothy Piers Clackson Breakdown of academic impact, for papers by Sabine Glaser Breakdown of academic impact, for papers by Luigi Cerbone Breakdown of academic impact, for papers by James D. Peyton Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by Gregory J. Gerstner Breakdown of academic impact, for papers by Kaiqi Du Breakdown of academic impact, for papers by Domnita-Ileana Burcoveanu Breakdown of academic impact, for papers by S.T. Kim
Rankless by CCL
2026